mgd020
mAbexperimental
Clinical trial activity
2 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 26, 2022 (NCT05261191)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3e
- Human immunodeficiency virusBINDING AGENT
Human immunodeficiency virus binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07217379 | Phase 1 | Oct 31, 2025 | Department of Defense, Henry M. Jackson Foundation for the Advancement of Military Medicine, National Institute of Allergy and Infectious Diseases (NIAID), United States Army, University of North Carolina at Chapel Hill |
| NCT05261191 | Phase 1 | Sep 26, 2022 | Department of Health and Human Services, MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 0 | 1 | 2022 |
| Department of Defense | Government | 1 | 0 | 1 | 2025 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2022 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 0 | 1 | 2025 |
| MacroGenics | For profit | 1 | 1 | 1 | 2022 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
| United States Army | Government | 1 | 0 | 1 | 2025 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2025 |
8 organizations
Page 1 / 1